Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$29.38 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $29.36 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Price, Consensus and EPS Surprise
IART 29.38 0.00(0.00%)
Will IART be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IART
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Should Retain Integra (IART) Stock Now
Why Is Integra (IART) Down 4% Since Last Earnings Report?
Integra LifeSciences (IART) Introduces MicroMatrix Flex
Other News for IART
Warning: IART is at high risk of performing badly
First Week of December 20th Options Trading For Integra LifeSciences Holdings (IART)
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary